528 reports of this reaction
1.6% of all AMPHOTERICIN B reports
#11 most reported adverse reaction
RENAL IMPAIRMENT is the #11 most commonly reported adverse reaction for AMPHOTERICIN B, manufactured by Astellas Pharma US, Inc.. There are 528 FDA adverse event reports linking AMPHOTERICIN B to RENAL IMPAIRMENT. This represents approximately 1.6% of all 32,295 adverse event reports for this drug.
Patients taking AMPHOTERICIN B who experience renal impairment should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RENAL IMPAIRMENT is a less commonly reported adverse event for AMPHOTERICIN B, but still significant enough to appear in the safety profile.
In addition to renal impairment, the following adverse reactions have been reported for AMPHOTERICIN B:
The following drugs have also been linked to renal impairment in FDA adverse event reports:
RENAL IMPAIRMENT has been reported as an adverse event in 528 FDA reports for AMPHOTERICIN B. This does not prove causation, but indicates an association observed in post-market surveillance data.
RENAL IMPAIRMENT accounts for approximately 1.6% of all adverse event reports for AMPHOTERICIN B, making it a notable side effect.
If you experience renal impairment while taking AMPHOTERICIN B, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.